Northeast Financial Consultants’s BioCryst Pharmaceuticals BCRX Stock Holding History

Northeast Financial Consultants’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$588K	Hold	65,633	–	–	0.02%	190
2025 Q1	$492K	Hold	65,633	–	–	0.02%	200
2024 Q4	$494K	Hold	65,633	–	–	0.02%	193
2024 Q3	$499K	Hold	65,633	–	–	0.02%	197
2024 Q2	$406K	Buy	65,633 +5,000	+8%	+$27.6K	0.02%	206
2024 Q1	$308K	Hold	60,633	–	–	0.02%	237
2023 Q4	$363K	Hold	60,633	–	–	0.02%	217
2023 Q3	$429K	Hold	60,633	–	–	0.03%	196
2023 Q2	$427K	Hold	60,633	–	–	0.03%	199
2023 Q1	$506K	Hold	60,633	–	–	0.03%	186
2022 Q4	$696K	Hold	60,633	–	–	0.05%	155
2022 Q3	$764K	Hold	60,633	–	–	0.06%	156
2022 Q2	$641K	Hold	60,633	–	–	0.04%	167
2022 Q1	$986K	Hold	60,633	–	–	0.06%	161
2021 Q4	$840K	Buy	60,633 +30,633	+102%	+$405K	0.05%	173
2021 Q3	$431K	Buy	30,000 +10,000	+50%	+$158K	0.03%	238
2021 Q2	$316K	Hold	20,000	–	–	0.02%	276
2021 Q1	$203K	Sell	20,000 -13,157	-40%	-$136K	0.02%	318
2020 Q4	$247K	Hold	33,157	–	–	0.02%	282
2020 Q3	$114K	Buy	33,157 +13,157	+66%	+$56.4K	0.01%	296
2020 Q2	$95K	Hold	20,000	–	–	0.01%	288
2020 Q1	$40K	Hold	20,000	–	–	﹤0.01%	264
2019 Q4	$69K	Hold	20,000	–	–	0.01%	301
2019 Q3	$57K	Hold	20,000	–	–	0.01%	318
2019 Q2	$76K	Hold	20,000	–	–	0.01%	322
2019 Q1	$163K	Hold	20,000	–	–	0.02%	308
2018 Q4	$161K	Hold	20,000	–	–	0.02%	149
2018 Q3	$152K	Hold	20,000	–	–	0.04%	148
2018 Q2	$114K	Hold	20,000	–	–	0.04%	144
2018 Q1	$95K	Hold	20,000	–	–	0.03%	145
2017 Q4	$98K	Hold	20,000	–	–	0.03%	152
2017 Q3	$105K	Hold	20,000	–	–	0.04%	149
2017 Q2	$111K	Hold	20,000	–	–	0.04%	141
2017 Q1	$168K	Hold	20,000	–	–	0.07%	145
2016 Q4	$127K	Hold	20,000	–	–	0.06%	139
2016 Q3	$88K	Hold	20,000	–	–	0.04%	152
2016 Q2	$57K	Hold	20,000	–	–	0.03%	147
2016 Q1	$57K	Hold	20,000	–	–	0.03%	133
2015 Q4	$206K	Hold	20,000	–	–	0.11%	123
2015 Q3	$228K	Hold	20,000	–	–	0.12%	119
2015 Q2	$299K	Hold	20,000	–	–	0.13%	116
2015 Q1	$181K	Buy	20,000 +10,000	+100%	+$104K	0.08%	137
2014 Q4	$121K	Hold	10,000	–	–	0.06%	129
2014 Q3	$98K	Buy	+10,000	New	+$123K	0.05%	132

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Northeast Financial Consultants's BCRX Position: Q2 2025 in Review

Northeast Financial Consultants held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2025 at 65,633 shares worth $588K. The position accounts for 0.02% of the portfolio, ranked #190.

Northeast Financial Consultants first reported a position in BCRX in Q3 2014 and has held it in 44 quarters since. The position peaked at $986K in Q1 2022. 294 funds tracked by Wall St. Rank hold BCRX as of Q2 2025.

Northeast Financial Consultants held 65,633 shares of BioCryst Pharmaceuticals worth $588K as of Q2 2025.
Northeast Financial Consultants left its BioCryst Pharmaceuticals share count unchanged in Q2 2025.
BioCryst Pharmaceuticals made up 0.02% of Northeast Financial Consultants's portfolio in Q2 2025, its #190 holding.
Northeast Financial Consultants first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 44 quarters since.
Northeast Financial Consultants's BioCryst Pharmaceuticals position peaked at $986K in Q1 2022.
294 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2025.

Based on Northeast Financial Consultants's 13F filing for Q2 2025, filed 15 Aug 2025.